Es gab 50 kürzliche Insider-Transaktionen für Deciphera Pharmaceuticals, Inc. (DCPH), darunter 27 Käufe und 22 Verkäufe. Die gesamten Insider-Käufe beliefen sich auf $12.24M und die gesamten Insider-Verkäufe auf $1.51M.
Bedeutende Insider mit kürzlicher Aktivität umfassen Brightstar Associates Llc, Sherman Matthew L, Kelly Thomas Patrick. Insider-Transaktionen können Einblicke geben, wie die Unternehmensführung die Bewertung und Zukunftsaussichten der Aktie einschätzt.
Insider-Transaktionen — DCPH
| Datum |
Name |
Funktion |
Transaktionsart |
Aktien |
Ø Preis |
Wert |
Gehaltene Aktien |
| 2024-04-22 |
Brightstar Associates Llc |
10 Percent Owner |
Optionsausübung (ITM) |
48,136 |
$0.01 |
$481.36 |
- |
| 2024-02-16 |
Sherman Matthew L |
EVP & Chief Medical Officer |
Informierter Verkauf |
2,615 |
$15.62 |
$40.84K |
108,739 |
| 2024-02-16 |
Kelly Thomas Patrick |
Chief Financial Officer |
Informierter Verkauf |
3,010 |
$15.62 |
$47.01K |
80,350 |
| 2024-02-16 |
Martin Daniel C. |
Chief Commercial Officer |
Informierter Verkauf |
2,267 |
$15.62 |
$35.41K |
55,118 |
| 2024-02-16 |
Pitman Jama |
SVP, Chief Development Officer |
Informierter Verkauf |
2,267 |
$15.62 |
$35.41K |
68,031 |
| 2024-02-15 |
Sherman Matthew L |
EVP & Chief Medical Officer |
RSU-Zuteilung |
69,100 |
$15.92 |
$1.1M |
69,100 |
| 2024-02-15 |
Kelly Thomas Patrick |
Chief Financial Officer |
RSU-Zuteilung |
69,100 |
$15.92 |
$1.1M |
69,100 |
| 2024-02-15 |
Hoerter Steven L. |
President and CEO |
RSU-Zuteilung |
298,100 |
$15.92 |
$4.75M |
298,100 |
| 2024-02-15 |
Martin Daniel C. |
Chief Commercial Officer |
RSU-Zuteilung |
38,900 |
$15.92 |
$619.29K |
38,900 |
| 2024-02-15 |
Dhanak Dashyant |
EVP & Chief Scientific Officer |
RSU-Zuteilung |
69,100 |
$15.92 |
$1.1M |
69,100 |
| 2024-02-15 |
Pitman Jama |
SVP, Chief Development Officer |
RSU-Zuteilung |
38,900 |
$15.92 |
$619.29K |
38,900 |
| 2024-02-07 |
Brightstar Associates Llc |
10 Percent Owner |
Optionsausübung (ITM) |
914,001 |
$0.01 |
$9.14K |
48,136 |
| 2024-01-16 |
Sherman Matthew L |
EVP & Chief Medical Officer |
Informierter Verkauf |
2,435 |
$14.47 |
$35.23K |
94,079 |
| 2024-01-16 |
Allen Patricia L |
Director |
RSU-Zuteilung |
4,727 |
$14.46 |
$68.35K |
4,727 |
| 2024-01-16 |
Kelly Thomas Patrick |
Chief Financial Officer |
Informierter Verkauf |
2,435 |
$14.47 |
$35.23K |
66,085 |
| 2024-01-16 |
Squarer Ron |
Director |
RSU-Zuteilung |
4,727 |
$14.46 |
$68.35K |
4,727 |
| 2024-01-16 |
Walsh Dennis Leo |
Director |
RSU-Zuteilung |
4,727 |
$14.46 |
$68.35K |
4,727 |
| 2024-01-16 |
Martin Daniel C. |
Chief Commercial Officer |
Informierter Verkauf |
1,624 |
$14.47 |
$23.5K |
47,660 |
| 2024-01-16 |
Friedman Franklin Stuart |
Director |
RSU-Zuteilung |
4,727 |
$14.46 |
$68.35K |
4,727 |
| 2024-01-16 |
Pitman Jama |
SVP, Chief Development Officer |
Informierter Verkauf |
1,624 |
$14.47 |
$23.5K |
50,573 |
| 2023-12-13 |
Sherman Matthew L |
EVP & Chief Medical Officer |
Informierter Verkauf |
2,792 |
$15.37 |
$42.9K |
96,514 |
| 2023-12-13 |
Kelly Thomas Patrick |
Chief Financial Officer |
Informierter Verkauf |
2,792 |
$15.37 |
$42.9K |
68,520 |
| 2023-12-13 |
Hoerter Steven L. |
President and CEO |
Informierter Verkauf |
30,664 |
$15.37 |
$471.22K |
72,763 |
| 2023-12-13 |
Martin Daniel C. |
Chief Commercial Officer |
Informierter Verkauf |
1,727 |
$15.37 |
$26.54K |
49,284 |
| 2023-12-13 |
Pitman Jama |
See Remarks |
Informierter Verkauf |
1,662 |
$15.37 |
$25.54K |
52,197 |
| 2023-12-12 |
Sherman Matthew L |
EVP & Chief Medical Officer |
RSU-Zuteilung |
8,244 |
- |
- |
99,306 |
| 2023-12-12 |
Kelly Thomas Patrick |
Chief Financial Officer |
RSU-Zuteilung |
8,244 |
- |
- |
71,312 |
| 2023-12-12 |
Hoerter Steven L. |
President and CEO |
RSU-Zuteilung |
62,500 |
- |
- |
103,427 |
| 2023-12-12 |
Martin Daniel C. |
Chief Commercial Officer |
RSU-Zuteilung |
5,576 |
- |
- |
51,011 |
| 2023-12-12 |
Pitman Jama |
See Remarks |
RSU-Zuteilung |
5,576 |
- |
- |
53,859 |
| 2023-11-30 |
Martin Daniel C. |
Chief Commercial Officer |
Informierter Verkauf |
17,801 |
$12.57 |
$223.76K |
45,435 |
| 2023-10-30 |
Sherman Matthew L |
EVP & Chief Medical Officer |
Informierter Verkauf |
2,360 |
$12.02 |
$28.36K |
90,628 |
| 2023-10-30 |
Kelly Thomas Patrick |
Chief Financial Officer |
Informierter Verkauf |
2,316 |
$12.02 |
$27.83K |
63,068 |
| 2023-10-30 |
Hoerter Steven L. |
President and CEO |
Informierter Verkauf |
21,573 |
$12.02 |
$259.26K |
40,927 |
| 2023-10-30 |
Martin Daniel C. |
Chief Commercial Officer |
Informierter Verkauf |
1,407 |
$12.02 |
$16.91K |
62,884 |
| 2023-10-30 |
Pitman Jama |
See Remarks |
Informierter Verkauf |
1,407 |
$12.02 |
$16.91K |
48,283 |
| 2023-10-28 |
Sherman Matthew L |
EVP & Chief Medical Officer |
RSU-Zuteilung |
8,244 |
- |
- |
92,988 |
| 2023-10-28 |
Kelly Thomas Patrick |
Chief Financial Officer |
RSU-Zuteilung |
8,244 |
- |
- |
65,384 |
| 2023-10-28 |
Hoerter Steven L. |
President and CEO |
RSU-Zuteilung |
62,500 |
- |
- |
62,500 |
| 2023-10-28 |
Martin Daniel C. |
Chief Commercial Officer |
RSU-Zuteilung |
5,576 |
- |
- |
64,291 |
| 2023-10-28 |
Pitman Jama |
See Remarks |
RSU-Zuteilung |
5,576 |
- |
- |
49,690 |
| 2023-10-02 |
Sherman Matthew L |
EVP & Chief Medical Officer |
Informierter Verkauf |
2,942 |
$12.68 |
$37.3K |
84,744 |
| 2023-09-15 |
Dhanak Dashyant |
EVP & Chief Scientific Officer |
RSU-Zuteilung |
65,900 |
- |
- |
65,900 |
| 2023-09-05 |
Dhanak Dashyant |
Officer |
Unbekannt |
- |
- |
- |
- |
| 2023-06-21 |
Allen Patricia L |
Director |
RSU-Zuteilung |
30,000 |
$14.91 |
$447.3K |
30,000 |
| 2023-06-21 |
Squarer Ron |
Director |
RSU-Zuteilung |
30,000 |
$14.91 |
$447.3K |
30,000 |
| 2023-06-21 |
Kelley Susan L. |
Director |
RSU-Zuteilung |
30,000 |
$14.91 |
$447.3K |
30,000 |
| 2023-06-21 |
Benz Edward J. Jr |
Director |
RSU-Zuteilung |
30,000 |
$14.91 |
$447.3K |
30,000 |
| 2023-06-21 |
Walsh Dennis Leo |
Director |
RSU-Zuteilung |
30,000 |
$14.91 |
$447.3K |
30,000 |
| 2023-06-21 |
Martin John Richard |
Director |
RSU-Zuteilung |
30,000 |
$14.91 |
$447.3K |
30,000 |
■ Informativ — Transaktion am offenen Markt (bedeutendste)
■ Nicht-informativ (Kauf) — Vergütung, Optionsausübung, Wandlung
■ Nicht-informativ (Verkauf) — Quellensteuer, Verkauf bei Vesting
■ Neutral — Schenkung, Treuhand, Verfall